The US FDA conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries ltd.'s Halol facility (Gujarat, India) from December 03-13, 2019. At the conclusion of the inspection, the agency issued a Form 483, with eight observations. The Company is preparing the response to the observations, which will be submitted to the US FDA within 15 business days. The Company is committed to addressing these observations promptly. The Company remains committed to working closely with the US FDA and continues to enhance its GMP compliance on an ongoing basis.
Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.438.65 as compared to the previous close of Rs. 433.8. The total number of shares traded during the day was 328914 in over 4217 trades.
The stock hit an intraday high of Rs. 441.9 and intraday low of 425.8. The net turnover during the day was Rs. 142722154.